ToxStrategies, a portfolio company of Renovus Capital Partners that provides scientific consulting services, has acquired Suttons Creek.
ToxStrategies is a multidisciplinary scientific consulting firm that provides toxicological, epidemiological, industrial hygiene, and therapeutic product development services to clients in the pharmaceutical, food and additives, consumer products, chemical, petrochemical, and pet sectors. The company, led by President Dr. Laurie Couture Haws, is headquartered near Houston in Katy, Texas, with additional offices across the United States and the United Kingdom.
Suttons Creek provides pharmaceutical companies with consulting services—conceptualization, device engineering, and quality assurance—for developing drug and medical device combinations. The company has supported the development of more than 120 individual drug and biologic delivery systems, including auto-injectors, prefilled syringes, infusion pumps, inhalers, and attached biosensors. Suttons Creek was founded in 2012 by Dr. Steven Badelt and is headquartered near Los Angeles in Westlake Village, California.
The acquisition of Suttons Creek expands and complements ToxStrategies’ capabilities in drug and biologic delivery systems.
Since being acquired by Renovus in January 2023, ToxStrategies has now completed three add-on acquisitions with the two earlier buys of Clintrex Research, a Florida-based provider of scientific, clinical trial, operational, and regulatory consulting services in June 2024, and Modality Solutions, a Texas-based provider of engineering and consulting services specializing in cold chain transportation and storage of biopharmaceutical products in August 2023.
“We are excited to welcome the Suttons Creek engineers, scientists, and regulatory specialists to our growing team of consultants,” said Dr. Couture Haws. “These experts work to assist clients in the pharmaceutical and medical device industries with the safety assessment, regulatory approval, commercialization, and transport of new, life-changing therapies and treatments.”
“ToxStrategies has generated significant momentum over the last year in terms of adding new service offerings to its life sciences practice,” said Jesse Serventi, a founding partner of Renovus. “We are thrilled to welcome Suttons Creek into the fold, bringing deep regulatory expertise to the medical device, pharmaceutical, and combination products industries. We are confident that this acquisition will allow ToxStrategies to deliver even more value to its clients and provide numerous growth opportunities for the company.”
Renovus Capital invests in companies active in the education, healthcare services, technology services, and professional services sectors with at least $3 million of EBITDA and enterprise valuations of $10 million to $200 million. Renovus was founded in 2010 and is based in the Philadelphia suburb of Wayne, Pennsylvania.
© 2024 Private Equity Professional | August 15, 2024
